Calls to improve vaccination uptake as UK loses ‘measles-free’ status

The UK has lost its ‘measles-free’ status after more than 250 cases of measures were reported during the first quarter of 2019. Now Prime Minister Boris Johnson has ordered urgent action to improve vaccination uptake.

Johnson visited a hospital in South Wales this week to lay out several measured design to improve vaccination rates – including for measles, mumps and rubella (MMR).

Although uptake for vaccination exceeds 90% for most childhood immunisations in the UK, there has been a small but steady decline in coverage in recent years.

This has led to the UK losing its ‘measles-free’ status with the World Health Organisation (WHO) just three years after the virus was eliminated in the country.

The WHO have stated that in the first six months of 2019 reported measles cases globally are almost three times as many as the same time last year.

Measles is now endemic in countries including France, Germany and Italy.

Johnson has now called for health leaders to renew their efforts to meet 95% for both doses of MMR.

Currently just 87% of children are getting their second dose of the jab, which has likely contributed to the spread of measles.

“With this strategy, the whole health system will come together to renew focus on vaccinations – especially for our children – and this time we will eliminate measles for good,” said Health Secretary Matt Hancock.

Measles elimination status means that the virus is no longer circulating permanently in a country.

The UK achieved measles-free status in 2016 after three years of limited spread due to high vaccination rates, but measles has since been spreading slowly in the UK for over 12 months.

Head of Immunisation at Public Health England Dr Mary Ramsay said: “Losing our ‘measles-free’ status is a stark reminder of how important it is that every eligible person gets vaccinated. Elimination can only be sustained by maintaining and improving coverage of the MMR vaccine.

“Measles is one of the most infectious diseases known to man – only one person travelling back to an area with lower vaccination rates can lead to an outbreak. Anyone who has not received two doses of MMR vaccine is always at risk.

“Making it as easy as possible for parents to access vaccines so that they can offer their children the best possible start in life is a priority for us, DHSC and for NHS England.

“Through our Value of Vaccines campaign, we’ll be using all opportunities to remind people to get two doses of MMR vaccine – whether that’s new parents, school children or younger adults. This will be crucial to the UK achieving elimination status again in future.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...